IKS · NSE
Inventurus Knowledge Solutions Limited
₹1,779.9
+2.95% (+₹51)
Prev. close
₹1,728.9
Volume
4,51,923
Delivery %
74.2%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts are split
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 0 bull / 1 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Downgraded Inventurus Knowledge Solutions (IKS Health) to 'hold' from 'buy', with a target price of ₹1,860 per share, wh…” | Jefferies AnalysisJefferies | Inventurus Knowledge Solutions | PENDING |
Fundamentals
About Inventurus Knowledge Solutions Limited
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform and associated services predominantly to healthcare enterprises in the United States, Canada, and Australia. The company offers a platform that serves healthcare organizations, including health systems/ integrated delivery networks, academic medical centers, multi-specialty medical groups, single-specialty medical groups, ancillary healthcare organizations, and other outpatient healthcare delivery organizations. Inventurus Knowledge Solutions Limited was incorporated in 2006 and is based in Navi Mumbai, India.
Details
Sector
Healthcare
Industry
Health Information Services
CEO
Mr. Sachin K. Gupta
Headquarters
Navi Mumbai
Employees
9,698
Website
ikshealth.comExchange
View on NSE ↗Key stats
Market cap
₹29,859.15 Cr
P/E ratio (TTM)
39.7
EPS (TTM)
₹44.78
Beta (1Y · daily vs NIFTY 50)
0.77
Shares float
4.10 Cr
EPS · quarter ended Jun 2026
₹11.32
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1,031.30 Cr | ₹1,816.91 Cr | ₹2,663.99 Cr | ₹3,193.79 Cr | |
| EBITDA | — | — | ₹389.26 Cr | ₹559.16 Cr | ₹808.71 Cr | ₹1,099.14 Cr |
| — | — | ₹305.23 Cr | ₹370.49 Cr | ₹486.06 Cr | ₹721.55 Cr | |
| Diluted EPS | — | — | ₹17.79 | ₹21.59 | ₹28.62 | ₹42.26 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Net income, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹988.31 Cr | ₹3,027.52 Cr | ₹3,051.84 Cr | ₹4,267.88 Cr | |
| — | — | ₹52.35 Cr | ₹1,311.09 Cr | ₹855.62 Cr | ₹752.52 Cr | |
| Stockholders' equity | ₹457.00 Cr | ₹647.00 Cr | ₹829.00 Cr | ₹1,158.00 Cr | ₹1,790.00 Cr | ₹2,800.00 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹175.00 Cr | ₹233.00 Cr | ₹288.00 Cr | ₹210.00 Cr | ₹318.00 Cr | ₹674.00 Cr | |
| Investing cash flow | — | — | ₹-155.96 Cr | ₹-1,141.28 Cr | ₹244.45 Cr | ₹-210.00 Cr |
| ₹-37.00 Cr | ₹-59.00 Cr | ₹-152.00 Cr | ₹780.00 Cr | ₹-389.00 Cr | ₹-412.00 Cr | |
| Capital expenditure | — | — | ₹-8.55 Cr | ₹-32.71 Cr | ₹-42.38 Cr | ₹-60.64 Cr |
| End cash position | — | — | ₹123.62 Cr | ₹-23.48 Cr | ₹146.16 Cr | ₹185.45 Cr |
Investing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|
| Promoter | 63.72% | 63.72% | 63.72% | 63.72% | 63.72% | 63.72% | 63.72% |
| Public | 33.43% | 33.70% | 33.71% | 33.82% | 33.91% | 33.97% | 34.05% |
| Employee trusts | 2.85% | 2.58% | 2.57% | 2.46% | 2.37% | 2.31% | 2.22% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Inventurus Knowledge Solutions Limited | ₹29,003.59 Cr | ₹1,779.9 | 38.7 | 10.36 | 25.8% | 0.27 | +19.9% | +15.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
24 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Inventurus Knowledge Q2 FY27: Date and Outlook
Inventurus Knowledge Solutions' Q2 FY27 results date is unconfirmed, with the company not yet filing a board meeting intimation as of September 10, 2026. Indian regulations require results to be published by November 14, 2026. The company's Q1 FY27 net profit was Rs 194.00 crore, compared to a Q2 FY26 profit of Rs 181.00 crore.
Inventurus Knowledge Solutions Shares Surge: Opens 43% Above Issue Price On Market Debut
News18 · 10 days ago